Atlas Trials

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Clinical trial NCT02730312 · COMPLETED

Trial details

NCT number
NCT02730312
Sponsor
Xencor, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Myelogenous LeukemiaB-cell Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia, Blast Crisis
Start date
2016-08-01
Primary completion
2021-09-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.